Amgen Inc. (NASDAQ:AMGN) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analysts have a consensus Hold on Amgen from 31 firms (2 sell, 14 hold, 14 buy, 1 strong buy) with an average 12‑month target of about $356.62.
• Amgen reported a clinical milestone completing an early Phase 1/2 MTAP‑null cancer combo study and will report Q1 2026 results on April 30, though pre‑earnings previews suggest a possible Q1 earnings decline that could drive near‑term volatility.
• Amgen beat last quarter’s estimates (EPS $5.29 vs. $4.76; revenue $9.87B, +8.6% YoY), set FY2026 EPS guidance of $21.60–$23.00, and declared a quarterly dividend of $2.52 ($10.08 annual, ~2.9% yield).

Shares of Amgen Inc. (NASDAQ:AMGN - Get Free Report) have been given an average rating of "Hold" by the thirty-one research firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation, fourteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $356.6154.

A number of research firms have recently commented on AMGN. Argus lifted their price objective on Amgen from $360.00 to $400.00 and gave the stock a "buy" rating in a research note on Friday, February 6th. Leerink Partners reiterated a "market perform" rating and issued a $355.00 price objective on shares of Amgen in a research note on Thursday, March 5th. UBS Group lifted their price objective on Amgen from $390.00 to $400.00 and gave the stock a "buy" rating in a research note on Monday, April 13th. Barclays began coverage on Amgen in a research note on Friday, February 20th. They issued an "equal weight" rating and a $350.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on Amgen from $285.00 to $295.00 and gave the stock a "hold" rating in a research note on Thursday, February 5th.

Hedge Funds Weigh In On Amgen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. High Note Wealth LLC increased its stake in Amgen by 5.8% during the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company's stock valued at $166,000 after acquiring an additional 28 shares during the period. TAGStone Capital Inc. increased its stake in Amgen by 0.7% during the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company's stock valued at $1,351,000 after acquiring an additional 28 shares during the period. Verus Capital Partners LLC increased its stake in Amgen by 2.3% during the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company's stock valued at $403,000 after acquiring an additional 28 shares during the period. Destination Wealth Management increased its stake in Amgen by 2.1% during the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company's stock valued at $456,000 after acquiring an additional 29 shares during the period. Finally, Breakwater Capital Group increased its stake in Amgen by 1.4% during the first quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company's stock valued at $717,000 after acquiring an additional 29 shares during the period. 76.50% of the stock is currently owned by institutional investors.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported completion of an early Phase 1/2 MTAP‑null cancer combination study — a clinical milestone that can de‑risk a development program and supports longer‑term oncology pipeline value. Company Study Completion
• Positive Sentiment: Guggenheim nudged its price target on AMGN to $351 (maintaining a Neutral rating), which signals modest analyst upside versus the stock’s trading range and can provide short‑term support. Guggenheim PT Update
• Neutral Sentiment: Amgen confirmed it will report Q1 2026 results after the market close on April 30 and will host a webcast — an obvious near‑term volatility driver as investors adjust positions into the print. Q1 Webcast
• Neutral Sentiment: Legislation (H.R. 8203) expanding workforce and treatment funding for substance use disorders was introduced; Amgen is listed among relevant healthcare companies — this is a longer‑horizon policy item that could modestly affect labor/training dynamics but is unlikely to move the stock immediately. H.R.8203 Bill
• Negative Sentiment: Pre‑earnings previews from Zacks and Yahoo Finance suggest AMGN may report a decline in Q1 earnings (reducing the odds of an earnings beat), which increases downside risk into the report. Earnings Preview
• Negative Sentiment: Insiders sold roughly US$4.1M of Amgen stock over the past year — sizable insider selling can be perceived as a cautionary signal by some investors. Insider Selling
• Neutral Sentiment: Amgen announced the planned retirement of EVP & Chief Technology Officer David M. Reese effective June 30, 2026, with a strategic leadership realignment — a governance event to watch, but presented as orderly and planned. CTO Retirement

Amgen Trading Down 1.2%

Amgen stock opened at $344.55 on Friday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The business's 50-day simple moving average is $360.74 and its 200-day simple moving average is $339.45. The firm has a market capitalization of $185.95 billion, a PE ratio of 24.21, a PEG ratio of 3.64 and a beta of 0.47. Amgen has a 52 week low of $261.43 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts' consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm's revenue for the quarter was up 8.6% on a year-over-year basis. During the same period in the previous year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts forecast that Amgen will post 22.18 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen's payout ratio is currently 70.84%.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.